

CLAIMS

1. A compound of Formula (**SI-4**):




SI-4 .

2. A pharmaceutically acceptable salt of a compound of Formula (**SI-4**)



SI-4 .


3. A pharmaceutical composition comprising a compound of Formula (**SI-4**)



SI-4

and a pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of Formula (**SI-4**) and a pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of Formula (**SI-4**)



SI-4

and a pharmaceutically acceptable excipient.

5. Use of an effective amount of a compound of claim 1 in the manufacture of a medicament for treating a CNS-related disorder related to GABA function, wherein the CNS-related disorder is a sleep disorder, an eating disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

6. The use of claim 5, wherein the CNS-related disorder is depression.

7. The use of claim 6, wherein the depression is post-partum depression.

8. The use of claim 6, wherein the depression is a major depressive disorder.

9. The use of claim 8, wherein the major depressive disorder is a moderate major depressive disorder or a severe major depressive disorder.

10. The use of claim 5, wherein the CNS-related disorder is tremor

11. The use of claim 10, wherein the tremor is essential tremor.

12. The use of claim 5, wherein the CNS-related disorder is an eating disorder.

13. The use of claim 12, wherein the eating disorder is anorexia nervosa, bulimia nervosa, binge-eating disorder, or cachexia.

14. The use of claim 5, wherein the CNS-related disorder is seizure.

15. The use of claim 5, wherein the CNS-related disorder is epilepsy.

16. The use of claim 5, wherein the CNS-related disorder is status epilepticus.

17. The use of claim 16, wherein the status epilepticus is convulsive status epilepticus or non-convulsive status epilepticus.

18. The use of claim 17, wherein the convulsive status epilepticus is early status epilepticus, established status epilepticus, refractory status epilepticus, or super-refractory status epilepticus.

19. The use of claim 17, wherein the non-convulsive status epilepticus is generalized status epilepticus or complex partial status epilepticus.

20. The use of claim 5, wherein the CNS-related disorder is bipolar disorder.

21. The use of any one of claims 5-20, wherein the compound is to be administered orally, subcutaneously, intravenously, or intramuscularly.

22. The use of claim 21 wherein the compound is to be administered chronically.

23. Use of an effective amount of a compound of claim 1 in the manufacture of a medicament for inducing sedation and/or anesthesia.